Publication

The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets

Smink, A. M., Li, S., Hertsig, D. T., de Haan, B. J., Schwab, L., van Apeldoorn, A. A., de Koning, E., Faas, M. M., Lakey, J. R. T. & de Vos, P., Apr-2017, In : Transplantation. 101, 4, p. E112-E119 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Smink, A. M., Li, S., Hertsig, D. T., de Haan, B. J., Schwab, L., van Apeldoorn, A. A., ... de Vos, P. (2017). The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets. Transplantation, 101(4), E112-E119. https://doi.org/10.1097/TP.0000000000001663

Author

Smink, Alexandra M ; Li, Shiri ; Hertsig, Don T ; de Haan, Bart J ; Schwab, Leendert ; van Apeldoorn, Aart A ; de Koning, Eelco ; Faas, Marijke M ; Lakey, Jonathan R T ; de Vos, Paul. / The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets. In: Transplantation. 2017 ; Vol. 101, No. 4. pp. E112-E119.

Harvard

Smink, AM, Li, S, Hertsig, DT, de Haan, BJ, Schwab, L, van Apeldoorn, AA, de Koning, E, Faas, MM, Lakey, JRT & de Vos, P 2017, 'The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets', Transplantation, vol. 101, no. 4, pp. E112-E119. https://doi.org/10.1097/TP.0000000000001663

Standard

The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets. / Smink, Alexandra M; Li, Shiri; Hertsig, Don T; de Haan, Bart J; Schwab, Leendert; van Apeldoorn, Aart A; de Koning, Eelco; Faas, Marijke M; Lakey, Jonathan R T; de Vos, Paul.

In: Transplantation, Vol. 101, No. 4, 04.2017, p. E112-E119.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Smink AM, Li S, Hertsig DT, de Haan BJ, Schwab L, van Apeldoorn AA et al. The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets. Transplantation. 2017 Apr;101(4):E112-E119. https://doi.org/10.1097/TP.0000000000001663


BibTeX

@article{6cac7f9497114e64a4ebe0c32f0cb1dd,
title = "The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets",
abstract = "Background. The liver as transplantation site for human pancreatic islets is a harsh microenvironment for islets and it lacks the ability to retrieve the graft. A retrievable, extrahepatic transplantation site that mimics the pancreatic environment is desired. Ideally, this transplantation site should be located subdermal for easy surgical-access but this never resulted in normoglycemia. Here, we describe the design and efficacy of a novel prevascularized, subcutaneously implanted, retrievable poly (D,L-lactide-co-epsilon-caprolactone) scaffold. Method. Three dosages of rat islets, that is, 400, 800, and 1200, were implanted in immune compromised mice to test the efficacy (n = 5). Islet transplantation under the kidney capsule served as control (n = 5). The efficacy was determined by nonfasting blood glucose measurements and glucose tolerance tests. Results. Transplantation of 800 (n = 5) and 1200 islets (n = 5) into the scaffold reversed diabetes in respectively 80 and 100{\%} of the mice within 6.8 to 18.5 days posttransplant. The marginal dose of 400 islets (n = 5) induced normoglycemia in 20{\%}. The glucose tolerance test showed major improvement of the glucose clearance in the scaffold groups compared to diabetic controls. However, the kidney capsule was slightly more efficacious because all 800 (n = 5) and 1200 islets (n = 5) recipients and 40{\%} of the 400 islets (n = 5) recipients became normoglycemic within 8 days. Removal of the scaffolds or kidney grafts resulted in immediate return to hyperglycemia. Normoglycemia was not achieved with 1200 islets in the unmodified skin group. Conclusions. Our findings demonstrate that the prevascularized poly (D,L-lactide-co-epsilon-caprolactone) scaffold maintains viability and function of islets in the subcutaneous site.",
keywords = "IN-VITRO, CELLS, MICE, CYTOMEGALOVIRUS, MICROCAPSULES, BIOMATERIALS, CULTURE, SHEETS, REPAIR, GRAFT",
author = "Smink, {Alexandra M} and Shiri Li and Hertsig, {Don T} and {de Haan}, {Bart J} and Leendert Schwab and {van Apeldoorn}, {Aart A} and {de Koning}, Eelco and Faas, {Marijke M} and Lakey, {Jonathan R T} and {de Vos}, Paul",
year = "2017",
month = "4",
doi = "10.1097/TP.0000000000001663",
language = "English",
volume = "101",
pages = "E112--E119",
journal = "Transplantation",
issn = "0041-1337",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "4",

}

RIS

TY - JOUR

T1 - The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-epsilon-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic Islets

AU - Smink, Alexandra M

AU - Li, Shiri

AU - Hertsig, Don T

AU - de Haan, Bart J

AU - Schwab, Leendert

AU - van Apeldoorn, Aart A

AU - de Koning, Eelco

AU - Faas, Marijke M

AU - Lakey, Jonathan R T

AU - de Vos, Paul

PY - 2017/4

Y1 - 2017/4

N2 - Background. The liver as transplantation site for human pancreatic islets is a harsh microenvironment for islets and it lacks the ability to retrieve the graft. A retrievable, extrahepatic transplantation site that mimics the pancreatic environment is desired. Ideally, this transplantation site should be located subdermal for easy surgical-access but this never resulted in normoglycemia. Here, we describe the design and efficacy of a novel prevascularized, subcutaneously implanted, retrievable poly (D,L-lactide-co-epsilon-caprolactone) scaffold. Method. Three dosages of rat islets, that is, 400, 800, and 1200, were implanted in immune compromised mice to test the efficacy (n = 5). Islet transplantation under the kidney capsule served as control (n = 5). The efficacy was determined by nonfasting blood glucose measurements and glucose tolerance tests. Results. Transplantation of 800 (n = 5) and 1200 islets (n = 5) into the scaffold reversed diabetes in respectively 80 and 100% of the mice within 6.8 to 18.5 days posttransplant. The marginal dose of 400 islets (n = 5) induced normoglycemia in 20%. The glucose tolerance test showed major improvement of the glucose clearance in the scaffold groups compared to diabetic controls. However, the kidney capsule was slightly more efficacious because all 800 (n = 5) and 1200 islets (n = 5) recipients and 40% of the 400 islets (n = 5) recipients became normoglycemic within 8 days. Removal of the scaffolds or kidney grafts resulted in immediate return to hyperglycemia. Normoglycemia was not achieved with 1200 islets in the unmodified skin group. Conclusions. Our findings demonstrate that the prevascularized poly (D,L-lactide-co-epsilon-caprolactone) scaffold maintains viability and function of islets in the subcutaneous site.

AB - Background. The liver as transplantation site for human pancreatic islets is a harsh microenvironment for islets and it lacks the ability to retrieve the graft. A retrievable, extrahepatic transplantation site that mimics the pancreatic environment is desired. Ideally, this transplantation site should be located subdermal for easy surgical-access but this never resulted in normoglycemia. Here, we describe the design and efficacy of a novel prevascularized, subcutaneously implanted, retrievable poly (D,L-lactide-co-epsilon-caprolactone) scaffold. Method. Three dosages of rat islets, that is, 400, 800, and 1200, were implanted in immune compromised mice to test the efficacy (n = 5). Islet transplantation under the kidney capsule served as control (n = 5). The efficacy was determined by nonfasting blood glucose measurements and glucose tolerance tests. Results. Transplantation of 800 (n = 5) and 1200 islets (n = 5) into the scaffold reversed diabetes in respectively 80 and 100% of the mice within 6.8 to 18.5 days posttransplant. The marginal dose of 400 islets (n = 5) induced normoglycemia in 20%. The glucose tolerance test showed major improvement of the glucose clearance in the scaffold groups compared to diabetic controls. However, the kidney capsule was slightly more efficacious because all 800 (n = 5) and 1200 islets (n = 5) recipients and 40% of the 400 islets (n = 5) recipients became normoglycemic within 8 days. Removal of the scaffolds or kidney grafts resulted in immediate return to hyperglycemia. Normoglycemia was not achieved with 1200 islets in the unmodified skin group. Conclusions. Our findings demonstrate that the prevascularized poly (D,L-lactide-co-epsilon-caprolactone) scaffold maintains viability and function of islets in the subcutaneous site.

KW - IN-VITRO

KW - CELLS

KW - MICE

KW - CYTOMEGALOVIRUS

KW - MICROCAPSULES

KW - BIOMATERIALS

KW - CULTURE

KW - SHEETS

KW - REPAIR

KW - GRAFT

U2 - 10.1097/TP.0000000000001663

DO - 10.1097/TP.0000000000001663

M3 - Article

VL - 101

SP - E112-E119

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -

ID: 39862437